Analysts at Barclays Capital (NYSE: BCS) lifted their price target on shares of Onyx Pharmaceuticals (NASDAQ: ONXX) from $40.00 to $44.00 in a research report issued to clients and investors on Thursday. The firm currently has an “equal weight” rating on the stock.
A number of other firms have also recently commented on ONXX. Analysts at Morgan Stanley (NYSE: MS) raised their price target on shares of Onyx Pharmaceuticals to $39.00 in a research note to investors on Thursday. They now have an “underweight” rating on the stock. Separately, analysts at Goldman Sachs (NYSE: GS) set a $52.00 price target on shares of Onyx Pharmaceuticals in a research note to investors on Thursday. They now have a “buy” rating on the stock. They also removed the stock from their conviction buy list on a valuation call. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Onyx Pharmaceuticals in a research note to investors on Friday, March 16th. They now have a $39.00 price target on the stock.
Onyx Pharmaceuticals traded down 0.47% on Thursday, hitting $42.47. Onyx Pharmaceuticals has a 52-week low of $27.17 and a 52-week high of $47.80. The company has a market cap of $2.705 billion and a price-to-earnings ratio of 39.55.
The company last announced its quarterly results on Wednesday, May 2nd. It reported ($0.68) earnings per share (EPS) for the previous quarter, missing the Thomson Reuters consensus estimate of ($0.60) EPS by $0.08. The company’s quarterly revenue was up 7.3% on a year-over-year basis. Analysts expect that Onyx Pharmaceuticals will post $-0.63 EPS next quarter.
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company engaged in developing therapies that target the molecular mechanisms that cause cancer.